Consistently, IPA revealed that C10 in both species are enriched for signaling pathways involved in multiple malignancies associated with KRAS mutation, i.e., NSCLC, as well as colorectal cancer, pancreatic ADC, ovarian cancer, acute myeloid leukemia, melanoma, and endometrial cancer (Supplementary Figure 3j). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.